# ZYME earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ZYME) · [Earnings tab](https://www.lopjlb.com/stock/ZYME?tab=earnings) Updated: 2026-08-06T05:34:00 Quarters analyzed: 8 ## Cross-quarter narrative Across the earnings calls, Zymeworks has demonstrated progress in its pipeline, with notable advancements in ZW171, ZW191, and ZW251. The company has also achieved significant milestones, including the approval of zanidatamab and the completion of the HORIZON-GEA-01 Phase III trial. Despite facing challenges such as regulatory risks, partner dependence, and cash burn, Zymeworks has maintained a strong cash balance and continues to repurchase shares. The company's narrative has shifted from focusing on early-stage pipeline progress to emphasizing regulatory milestones, commercial uptake, and cash runway management. ## Latest CallCard · Q1 Zymeworks reported Q1 2026 revenue drop, highlighted upcoming PDUFA approval for zanidatamab, progress on pan‑RAS ADC preclinical data, strong cash balance and ongoing share‑repurchase, while noting reliance on future milestone payments. **Guidance:** maintained — Management reaffirmed that existing cash and anticipated $440 million in milestone payments should fund operations beyond 2028. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.2 Prepared remarks emphasized regulatory milestones, pipeline progress and disciplined capital allocation, conveying optimism. ### Demand visibility Regulatory milestones provide near‑term visibility. PDUFA date set for Aug 25 2026 for zanidatamab in first‑line GEA, sBLA filing completed in China, and $250 M US plus $15 M China milestone payments expected upon approval. ### Margins / costs Operating expenses decreased YoY. R&D expense fell due to lower third‑party program costs, partially offset by early‑stage investments; G&A declined from lower professional fees despite higher salaries from leadership transition. ### Capital allocation Disciplined capital allocation with active share‑repurchase. $95.8 M of the $125 M repurchase program used to buy 3.93 M shares at $24.37 avg.; cash resources $403.8 M as of Mar 31 2026, supporting operations and anticipated milestone cash runway. ### Milestones - **Zanidatamab PDUFA filing** [on_track]: PDUFA date Aug 25 2026 for first‑line HER2‑positive GEA in the U.S. - **China sBLA filing for GEA** [on_track]: Completion of sBLA filing provides additional regulatory visibility. - **Near‑term milestone payments** [on_track]: Expected $250 M US and $15 M China payments upon zanidatamab approvals. - **Pan‑RAS ADC preclinical data at AACR** [delivered]: Three new preclinical ADC candidates (ZW439, Z427,A‑6E, ZW418) presented with favorable PK/PD. - **Share repurchase program** [on_track]: ~$95.8 M deployed, supporting shareholder returns. - **Leadership appointments** [new]: Added CFO Kristin, CBO Scott, R&D head Adam and General Counsel Paul Schneider. ### Fears / risks - **Regulatory risk**: Approval of zanidatamab hinges on meeting the Aug 2026 PDUFA timeline and Chinese sBLA outcomes. - **Commercial uptake**: Revenue growth depends on successful launch and royalty generation from zanidatamab sales. - **Technology risk**: Pan‑RAS ADC efficacy and safety are still preclinical; toxicity profile remains uncertain. - **Cash burn**: Net loss widened to $44.2 M; continued operating expenses require milestone payments to sustain runway. - **Partner dependence**: Revenue decline tied to reduced milestones and drug‑supply revenue from Jazz partnership. - **Leadership transition costs**: Higher salaries and unallocated costs from recent executive hires increase G&A. - **Market perception**: Reliance on future royalty streams may be viewed skeptically by investors. - **Execution risk**: Multiple concurrent ADC programs could stretch resources and delay individual candidate timelines. ## Quarter one-liners - **2026 Q1:** Zymeworks reported Q1 2026 revenue drop, highlighted upcoming PDUFA approval for zanidatamab, progress on pan‑RAS ADC preclinical data, strong cash balance and ongoing share‑repurchase, while noting reliance on future milestone payments. - **2025 Q4:** Zymeworks reported strong Phase III HORIZON‑GEA‑01 results, expects US zanidatumab BLA submission in 2026, secured a $250M royalty‑backed note and is aggressively repurchasing shares while maintaining cash runway beyond 2028. - **2025 Q3:** ZYME reported Q3 2025 revenue jump to $27.6M driven by a $25M J&J milestone, early Phase I data for ZW191, first patient dosed in ZW251, and continued share repurchases, while noting the discontinuation of ZW171 and a cash runway to H2 2027. - **2025 Q2:** Zymeworks Q2 2025: $48.7M revenue (BeOne/BMS milestones), $333M cash, 3 Phase I programs (ZW171/191/251), HERIZON-GEA-01 PFS readout Q4, partnering discussions across portfolio. Cash runway into H2 2027 with milestones. Zanidatamab royalties emerging from China/EU approvals. ZW1528 COPD bispecific p - **2025 Q1:** Zymeworks narrowed its Q1 2025 net loss, boosted revenue with partnership milestones, highlighted pipeline progress including an IND slated for ZW209 in H1 2026, and said its cash will fund operations into H2 2027. - **2024 Q4:** Zymeworks reports Q4 2024 with zanidatamab approval, $324M cash runway into H2 2027, $45M partnership milestones, and advancing wholly-owned pipeline (ZW171, ZW191, ZW209, ZW220, ZW251). - **2024 Q3:** Zymeworks advances wholly-owned pipeline with ZW171 and ZW191 Phase 1 dosing, ADC preclinical progress, $374.9M cash runway into H2 2027, and upcoming R&D - **2024 Q2:** Zymeworks reports Q2 2024 results, advances ZW171/ZW191 into clinic, discontinues Zani-Zo, expects zanidatamab BLA decision Nov 2024, cash runway into H2 2027, announces $30M share buyback.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Prepared remarks highlight regulatory progress (priority review, IND ## Theme arcs - **Pipeline Progress** (improving): ZW171, ZW191, and ZW251 advancements - **Regulatory Milestones** (improving): Zanidatamab approval and HORIZON-GEA-01 trial completion - **Cash Runway Management** (stable): Strong cash balance and share repurchases - **Partner Dependence** (deteriorating): Reliance on Jazz and BeiGene for submissions and commercialization - **Commercial Uptake** (new): Focus on successful launch and royalty generation from zanidatamab sales ## Fear persistence - **Regulatory Risk** [recurring]: Approval timelines and meeting interim analysis thresholds - **Partner Dependence** [recurring]: Reliance on Jazz and BeiGene for submissions and commercialization - **Cash Burn** [recurring]: Net loss widened to $44.2M; continued operating expenses require milestone payments to sustain runway - **Commercial Uptake** [new]: Revenue growth depends on successful launch and royalty generation from zanidatamab sales - **Technology Risk** [new]: Pan-RAS ADC efficacy and safety are still preclinical; toxicity profile remains uncertain ## Guidance path 2024 Q2:vague → 2024 Q3:vague → 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/ZYME`